Epitan Limited

Trial of melanin-stimulating topical fomulation EPT1647 begins in London

Published in Law and Health Weekly, November 19th, 2005

Epitan Limited (EPT), Melbourne, Australia, announced the commencement of a clinical trial in London, UK, to test a newly developed topical (spray on lotion) formulation for its melanin-inducing drug EPT1647 (formerly Melanotan). The first volunteers were recruited this week to receive their first dose of EPT1647.

Melanotan, according to the company's web site, stimulates the body to make melanin, which causes a tan and is known to protect the body from skin damage as a result of sunburn, a known prime cause of skin cancer. In short, Melanotan, induces a protective tan without exposure to UV radiation.

The trial is being overseen by the William...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2005-11-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry